Oncology / HCC

Background of HCC

1. 90% of HCC patients die within 5 years after Diagnosis
2. 50% OF HCC patients die within 2 years after diagnosis.
3. 840,000 annual new HCC cases globally, and 35,000 annual new HCC cases in the US.
4. HCC Treatment is a Large and Growing Market

Current Treatment for HCC

1. Sorafenib and other chemotherapies (first-line treatment)

• Extends survival by only 12 weeks
• High relapse/refractory rate

2. PD-1/PD-L1 blockades (second-line treatment)

• Less than 20% overall response rate
• Resistance to PD-1 and PD-L1 blockade

3. Marginally effective standard of care

CD147-CAR-NK is promising for HCC treatment

1. CD147-CAR-NK cells can effectively kill various malignant HCC cell lines in vitro.
2. CD147-CAR-NK cells control the growth of HCC tumors in multiple xenograft and patient-derived xenograft mouse models.
3. CD147-CAR-NK cells does not cause severe on-target/off-tumor toxicity in a human CD147 transgenic mouse model.